Searched for
AUROBINDO PHARMA EBITDA MARGIN
RIL Q2 Results: Nuvama sees 17% EBITDA growth, led by O2C biz. Here’s what to expectReliance Industries is expected to report 17% year-on-year growth in Q2FY27 EBITDA to Rs 53,700 crore, led by stronger refining margins and...- Fortis, Apollo, other hospital stocks slump up to 10% in 2 days after SC questions steep markups. Buying opportunity?Hospital stocks extended losses for a second session after the Supreme Court questioned steep markups on cancer drugs and raised concerns o...
- Jefferies picks 6 hospitals as Buy after steep correction offers 'excellent' entry points. Check target priceJefferies has maintained a Buy rating on six hospital stocks, including Apollo Hospitals and Fortis Healthcare, following a sharp correctio...
- Solar Industries’ Omnia acquisition to reshape growth, debt outlookSolar Industries is performing well in the market despite broader weaknesses, primarily due to strong earnings. The planned acquisition of ...
- ChrysCapital to take minority stake in Linux laboratoriesLinux Laboratories has secured $70 million in equity funding from ChrysCapital and Tata Capital Healthcare Fund III. This investment involv...
- Cupid shares rally 16% in two sessions. What’s behind the sharp uptick in the multibagger stock?Cupid shares surged 7% after entering the Nifty Smallcap 250 index, extending gains to 16% in two sessions. The company has raised FY27 rev...
- Morgan Stanley raises Lenskart target price to Rs 718; bull case implies 41% upside. Here’s whyLenskart Solutions reported a 182.3% YoY rise in Q1 FY27 net profit to Rs 228 crore, while revenue grew 33.6% to Rs 2,214 crore. EBITDA mar...
- FIIs dump telecom for 8th straight month, outflows cross Rs 32,000 crore. Are stocks set for rebound?Foreign portfolio investors have dumped Indian telecom stocks for the eighth consecutive month, pulling out over Rs 32,000 crore in CY26. H...
- Cupid shares end 10% higher ahead of Nifty Smallcap 250 inclusion tomorrow. How much inflows can it see?Cupid shares jumped 10% to Rs 291 after the company’s inclusion in the Nifty Smallcap 250 index, effective September 30. The stock has surg...
- Motilal Oswal sees Aster DM EBITDA rising 25% CAGR through FY28; sets Rs 910 targetMotilal Oswal has initiated coverage on Aster DM Quality Care with a Buy rating and Rs 910 target, citing merger synergies, capacity expans...
- Anupam Rasayan completes Bliss GVS deal, targets Rs 4,000-crore integrated platformAnupam Rasayan India Limited has finalised its acquisition of a controlling interest in Bliss GVS Pharma, marking a strategic expansion int...
- Honasa Consumer shares fall 5% after Rs 643 crore block deal; Peak XV, Sequoia likely sellersHonasa Consumer shares declined up to 5% after 1.4 crore shares worth Rs 643 crore changed hands in a block deal. The transaction comes aft...
- Sun Pharma, Aurobindo Pharma, other stocks in focus as Trump exempts India from 100% tariffs on some speciality drugsIndian pharma stocks, including Sun Pharma and Aurobindo Pharma, are in focus after the US exempted India and 19 other countries from 100% ...
- Goldman Sachs sees Eternal achieving $1 billion EBITDA by FY29; raises target priceGoldman Sachs maintained a Buy rating on Eternal, formerly Zomato, raising its target price by 11% to Rs 385. The brokerage foresees Eterna...
- Moneyview vs Orient Cables vs A-One Steels: Which IPO could give strong listing gains and long-term growth?Currently, three mainboard IPOs are capturing the interest of investors: Moneyview, Orient Cables, and A-One Steels. Each presents unique g...
- Suzlon Energy shares fall 2% to near six-month low, down 15% in one monthSuzlon Energy shares slipped over 2% to a near six-month low, approaching their 52-week low amid higher trading volumes and broader market ...
- NSE becomes world's sixth largest bourse with $47 billion m-capThe National Stock Exchange of India has recently reached an impressive market capitalisation nearing $47 billion. Shares began trading at ...
- Can Runwal Enterprises IPO deliver long-term growth for high-risk investors?In an effort to improve its financial health, Runwal Enterprises is set to raise ₹500 crore through a fresh issue primarily aimed at debt r...
- Pharma sector revenue to grow 11-13 pc in FY27 on strong exports, domestic demand: CrisilIndia's pharmaceutical sector is projected to grow at 11-13 percent this fiscal year due to export increases. The domestic market is also e...
- JM Financial sees up to 28% upside in Dr Reddy’s and Aurobindo Pharma. Should you buy?JM Financial retained Buy ratings on Dr Reddy’s Laboratories and Aurobindo Pharma, seeing up to 28% upside over the next 12 months. The bro...
Load More
